Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With Right Heart Failure Caused by Pulmonary Arterial Hypertension

NCT05569655 is registered in ClinicalTrials.gov with Chinese Pulmonary Vascular Disease Research Group as lead sponsor.

NCT NCT05569655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05569655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With Right Heart Failure Caused by Pulmonary Arterial Hypertension
Lead sponsor
Chinese Pulmonary Vascular Disease Research Group
Phase
Not applicable
Overall status
Unknown status
Start date
April 6, 2021
Completion date
December 31, 2022
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension, randomized controlled trial